Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | CPA1 | P15085 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26965384 | 1.00 | ALDH1A1 (0.38) | ALDH1A1LMNAMEN1KMT2ACYP2D6 | |
| SCHEMBL15511096 | 0.81 | CYP2D6 (0.42) | CYP2D6CYP2C19MAPT | |
| SCHEMBL2086407 | 0.79 | CA12 (0.38) | LMNA | |
| SCHEMBL27651567 | 0.77 | ALDH1A1 (0.42) | ALDH1A1LMNAMEN1KMT2ACYP2D6 | |
| SCHEMBL16329867 | 0.77 | TAS1R3 (0.44) | ALDH1A1LMNAMEN1KMT2ACYP2D6 | |
| SCHEMBL25291547 | 0.77 | ALDH1A1 (0.42) | ALDH1A1LMNAMEN1KMT2ACYP2D6 | |
| SCHEMBL3306198 | 0.77 | ALDH1A1 (0.42) | ALDH1A1LMNAMEN1KMT2ACYP2D6 | |
| SCHEMBL3374592 | 0.75 | AAK1 (0.49) | CYP2D6 | |
| SCHEMBL24387777 | 0.75 | AAK1 (0.49) | CYP2D6 | |
| SCHEMBL9735086 | 0.75 | CACNA2D1 (0.45) | ALDH1A1LMNAMEN1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
| WO-2012000608-A2 | NOVEL BETA-AMINOALDEHYDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR CHEMICAL USE AS REACTIVE INTERMEDIATES | GLUESENKAMP KARL-HEINZ (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | ALDH1A1 1457/4885LMNA 2655/4885MEN1 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.